X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Divis Laboratories Fact Sheet, Divis Laboratories Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Divis Laboratories Fact Sheet   (DIVI)

Here is the latest financial fact sheet of Divis Laboratories. For more details, see the Divis Laboratories quarterly results and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.

DIVIS LABORATORIES Price History

Price Rs 641.0
Mkt Cap Rs m 170,165
Vol '000 18.7
P/E X 16.2
P/CF X 13.8
EPS (TTM) Rs 39.7
% ch % 0.1
No. of shares m 265.47
% ch week % -2.5
% ch 1-mth % 7.6
% ch 12-mth % -42.2
52 week H/L Rs 1,380.0/533.1
(As on Jun 23, 2017 10:41:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DIVIS LABORATORIES Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
DIVIS LABORATORIES EQUITY SHARE DATA
High Rs8431,2331,4591,8812,484 
Low Rs6687529051,217918 
Sales per share (Unadj.) Rs140.4161.6190.8234.7142.3 
Earnings per share (Unadj.) Rs40.245.458.364.241.9 
Diluted earnings per shareRs20.122.729.132.141.9 
Cash flow per share (Unadj.) Rs44.951.265.274.446.3 
Dividends per share (Unadj.) Rs13.0015.0020.0020.0010.00 
Adj. dividends per shareRs6.507.5010.0010.0010.00 
Dividend yield (eoy) %1.71.51.71.30.6 
Book value per share (Unadj.) Rs160.6188.4223.3263.3161.5 
Adj. book value per shareRs80.394.2111.6131.7161.5 
Shares outstanding (eoy) m132.73132.73132.73132.73265.47 
Bonus/Rights/Conversions  ESOP---- 
Price / Sales ratio x5.46.16.26.612.0 
Avg P/E ratio x18.821.920.324.140.6 
P/CF ratio (eoy) x16.819.418.120.836.7 
Price / Book Value ratio x4.75.35.35.910.5 
Dividend payout %32.433.134.331.223.9 
Avg Mkt Cap Rs m100,278131,735156,887205,599451,525 
No. of employees `000NANANANA3.7 
Total wages/salary Rs m1,5091,9772,3252,9043,649 
Avg. sales/employee Rs ThNMNMNMNM10,184.4 
Avg. wages/employee Rs ThNMNMNMNM984.1 
Avg. net profit/employee Rs ThNMNMNMNM2,998.5 
DIVIS LABORATORIES INCOME DATA
Net Sales Rs m18,63921,44825,32131,14937,764 
Other income Rs m561448706447848 
Total revenues Rs m19,19921,89726,02731,59638,612 
Gross profit Rs m6,9048,15210,14511,65214,138 
Depreciation Rs m6217709211,3601,182 
Interest Rs m3718211923 
Profit before tax Rs m6,8067,8129,90910,72113,781 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,4741,7922,1762,2062,662 
Profit after tax Rs m5,3336,0207,7338,51511,119 
Gross profit margin %37.038.040.137.437.4 
Effective tax rate %21.722.922.020.619.3 
Net profit margin %28.628.130.527.329.4 
DIVIS LABORATORIES BALANCE SHEET DATA
Current assets Rs m17,51018,64122,56427,72430,947 
Current liabilities Rs m5,5385,5456,2747,7555,195 
Net working cap to sales %64.261.164.364.168.2 
Current ratio x3.23.43.63.66.0 
Inventory Days Days133142134136117 
Debtors Days Days97871048785 
Net fixed assets Rs m9,20412,12113,66315,27117,027 
Share capital Rs m266266266266531 
"Free" reserves Rs m21,04524,73529,36334,68342,341 
Net worth Rs m21,31525,00629,63434,95442,877 
Long term debt Rs m262116115 
Total assets Rs m27,56731,38837,10544,11449,684 
Interest coverage x183.0439.9482.0577.4595.0 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.70.70.70.8 
Return on assets %19.519.220.919.322.4 
Return on equity %25.024.126.124.425.9 
Return on capital %32.131.333.530.732.2 
Exports to sales %86.286.789.284.385.3 
Imports to sales %19.521.820.023.922.9 
Exports (fob) Rs m16,06918,60222,57526,24432,198 
Imports (cif) Rs m3,6384,6815,0697,4428,654 
Fx inflow Rs m16,15118,78922,61726,31732,270 
Fx outflow Rs m3,7194,7965,1837,5888,775 
Net fx Rs m12,43213,99317,43418,72923,496 
DIVIS LABORATORIES CASH FLOW
From Operations Rs m 3,384 4,800 5,568 8,263 10,379 
From Investments Rs m -2,044 -2,545 -3,052 -5,208 -4,135 
From Financial Activity Rs m -1,311 -2,308 -2,485 -3,030 -6,241 
Net Cashflow Rs m 28 -53 31 25 3 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.8%
FIIs 19.0%
ADR/GDR 0.0%
Free float 17.2%
Shareholders 31,796
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 7-1-77/E/1/303, Divi Towers, Dharam Karan Road, Ameerpet, Hyderabad-16
E-MAIL cs@divislaboratories.com WEB www.divislaboratories.com
TELEPHONE (040) 2378 6300 FAX (040) 2378 6460
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR P. V. R. K. Nageswara Rao & Co.
CHM: Murali K. Divi (MD) COMP SEC: P. V. Lakshmi Rajani YEAR OF INC: 1990 BSE CODE: 532488 FV (Rs): 2 DIV YIELD (%): 1.6

More Pharmaceuticals Company Fact Sheets:   PFIZER  NATCO PHARMA  FULFORD INDIA  GLENMARK PHARMA  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   PFIZER  NATCO PHARMA  FULFORD INDIA  GLENMARK PHARMA  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Off to a Cautious Start; Realty & Power Stocks Gain(09:30 am)

Most of the Asian equity markets are lower today after the sell-off in mainland China markets in the previous trading session. The Shanghai Composite is off 0.13% while the Hang Seng is down 0.21%.

Views on news

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Should You Trade In Mutual Funds As You Do In Stocks?(Outside View)

Jun 10, 2017

Trading is not synonymous with mutual funds, PersonalFN explains.

Which Way Will Inflation Go?(Chart Of The Day)

Jun 10, 2017

RBI and government at loggerheads over interest rates.

More

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ORCHID PHARMA LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS